Atlanta 9/21/2013 3:00:00 AM
News / Stocks

MissionIR News - Seeking Alpha Publishes Article Featuring CytRx Corp.

MissionIR would like to highlight CytRx Corp. (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology. The company’s pipeline is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin. The Company also has rights to two additional drug candidates, tamibarotene and bafetinib.

In the company’s news,

Seeking Alpha yesterday published the following article featuring CytRx:

The article titled “CytRx Corporation Remains an Undiscovered Opportunity in the Cancer Space” provides an overview of the rapid growth taking place in emerging economies around the world. Featured alongside large-cap plays Celldex Therapeutics (NASDAQ: CLDX) and Seattle Genetics (NASDAQ: SGEN), CytRx was noted as being a compelling opportunity with significant potential in the oncology market.

The author of the article, penned under the name Equity Options Guru, writes: “Although CytRx is still a small company in terms of market capitalization, the fact remains that it is quickly becoming a diversified powerhouse with the potential to treat several illnesses within the oncology space. Given all the potential, it's surprising that the rest of the market hasn't caught on yet.”

For more information on CytRx Corp., visit  

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

To sign up for The MissionIR Report, please visit

To connect with MissionIR via Facebook, please visit

To connect with MissionIR via Twitter, please visit

Please read FULL disclaimer on the MissionIR website:

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.